We can’t show the full text here under this license.
Computer-designed new triazole-thiazolidinedione-coumarin compounds tested as diabetes treatments
Updated
Abstract
Compound I-1 demonstrated an IC value of 1.49 µg/ml against the α-glucosidase enzyme.
- Molecular docking studies indicated that Compound I-1 is a promising scaffold for drug design targeting α-glucosidase.
- In vivo studies showed that Compound I-1 significantly lowered blood glucose levels to 94.15 mg/dL and 74.60 mg/dL at doses of 10 mg/kg and 20 mg/kg, respectively.
- Compounds I-1 resulted in significant reductions in liver and kidney function markers, including ALT, AST, ALP, urea, LDH, and creatinine levels.
- Pharmacokinetic evaluations suggested favorable drug-likeness and ADMET properties for Compound I-1.
- Density functional theory analyses provided insights into the stability and reactivity of Compound I-1 as a diabetes treatment candidate.
Simplified
Key numbers
1.49 µg/ml
of Compound I-1
In vitro α-glucosidase inhibition assay results
94.15 mg/dL
Blood glucose levels at 10 mg/kg
In vivo antidiabetic activity study results
74.60 mg/dL
Blood glucose levels at 20 mg/kg
In vivo antidiabetic activity study results